← all companies · 2026-07-07 · moat: narrow · raw .md

Cipla: Three Things That Must Work at Three in the Morning

The attack

It is three in the morning and a child cannot breathe.

The airways in her lungs — the branching tubes that carry air to the tiny sacs where blood collects oxygen — are lined with muscle. In an asthma attack that muscle clamps down and the lining swells, and the tubes that should be open squeeze to slits. Air can get in but struggles to get out; the chest heaves, the breath whistles, panic makes the muscle clench harder. She needs a drug that relaxes that muscle within seconds. Not within an hour, when a swallowed tablet would finally reach her bloodstream — within seconds.

There is only one route fast enough: send the medicine straight to the lungs themselves. And that single requirement — deliver a drug directly to the airway, now — turns out to be one of the hardest engineering problems in all of medicine, harder in its way than making the drug at all. To understand Cipla, one of the companies that solved it, you have to understand why putting a medicine into a lung is so much more difficult than putting one into a stomach.

The physics of a breath you can medicate

Start with the target. The lung is not one chamber but a fractal tree that divides some twenty-three times, ending in about three hundred million tiny air sacs. The useful drug has to land on the airway walls partway down that tree — not in the mouth, not swallowed, not blown straight back out. And whether a particle lands there is governed almost entirely by one thing: its size.

Picture particles of medicine riding the incoming stream of air. A large particle — bigger than about five microns, five thousandths of a millimetre — has too much momentum; when the airstream bends at the back of the throat, the particle can't turn the corner and it slams into the tissue and is swallowed, useless. A very small particle — below about one micron — is so light it simply floats in and floats back out on the next breath, like smoke, never settling. Only particles in a narrow window, roughly one to five microns, are heavy enough to sink onto the airway wall but light enough to get deep before they do. Make your powder in that window and it works; miss it by a factor of two and the same drug does nothing. This is not chemistry. This is aerodynamics — the same physics that decides whether dust settles or drifts — and it is the first thing that makes an inhaler hard.

Now the second problem: how do you get a solid drug into that size window and keep it there? You mill it into an ultra-fine powder, but fine powders are sticky and clump — and a clump is a large particle again. So a dry-powder inhaler blends the drug with a carrier, times its release to your in-breath, and relies on the force of your own inhalation to shear the clumps apart in the final instant. A pressurised metered-dose inhaler — the familiar puffer — takes a different route: it dissolves or suspends the drug in a liquefied propellant gas under pressure, and when you press it, a metered dose sprays out and the propellant flash-evaporates in mid-air, leaving behind a cloud of particles of exactly the right size, if — and only if — the formulation and the valve and the nozzle geometry are tuned together perfectly.

And the third problem, the human one: the patient. A tablet works the same whoever swallows it. An inhaler's dose depends on how the patient breathes — too weak an inhalation and a dry-powder device never shears the clumps; poor timing on a puffer and the cloud hits a closed mouth. So the device has to be forgiving of imperfect humans at three in the morning, which is a design discipline all its own.

Hold those three together, because they are the whole point. An inhaled medicine is not a drug. It is a drug plus a device plus a lung, and the three are inseparable — the particle size, the propellant, the valve, the patient's breath all have to agree. That is the thing Cipla makes.

Why "drug plus device plus lung" resists copying

Recall the merciless law of the generics world: a molecule is a molecule, so the day a drug's patent expires anyone can reproduce it and the price collapses. That law is why most of pharma is a treadmill.

The respiratory business partly escapes that law, and the escape is physical, not legal. When you copy a tablet, you need only prove your molecule is identical and dissolves the same way — straightforward chemistry. When you copy an inhaler, proving the molecule is identical is the easy part. You must also reproduce the particle-size distribution, the way the plume sprays, the dose delivered at a weak breath and a strong one, and — crucially — you must prove to regulators that your device puts the same amount of drug into the same part of the lung as the original. Two inhalers with chemically identical medicine can deliver wildly different doses to the airway because their aerodynamics differ. So the regulator cannot simply wave the copy through on chemistry; it demands device studies, sometimes clinical studies, that take years and cost far more than copying a pill.

The result is that inhaled generics are a scarce club. Where a plain tablet might attract a dozen copiers within months of a patent lapsing, a complex inhaler might attract two or three over several years — and two or three competitors is oligopoly, where sellers earn real margins, rather than the commodity scramble of a crowded generic. The moat here is not a patent with an expiry date. It is the sheer physical and regulatory difficulty of proving that your cloud of particles behaves like someone else's cloud of particles. That difficulty does not expire.

Cipla built exactly this kind of franchise. It has been a respiratory house for decades — inhalers, the drugs that go in them, and the manufacturing know-how to make particles in the right size window at scale. That is the durable core hiding inside a company that, on the surface, also does plenty of ordinary generics.

From a defiant founder to a global generic house

Cipla was incorporated in 1935, which makes it one of the oldest names in Indian industry — older than independent India itself. Its founder, Khwaja Abdul Hamied, built it in the explicit belief that Indians should not depend on foreign firms for their medicines, and the company's defining moment came much later, in 2001, when it offered to make anti-retroviral drugs for HIV/AIDS at a fraction of Western prices — a decision that helped turn a death sentence into a manageable illness across Africa and made Cipla globally famous as the drugmaker that put access above margin.

That history matters because it shaped a culture: Cipla has always been part commercial enterprise, part public-health mission, and the two impulses pull in different directions on price. The respiratory franchise grew out of the same soil — India has an enormous burden of asthma and lung disease, much of it made worse by air pollution, and a company serving that need at home naturally built world-class inhaler capability that it could then carry abroad.

You can see the ambivalence in the ownership. The founding family's promoter stake has been drifting down — from 33.46% to 29.22% over recent years, a decline the company itself flags — while domestic institutions have stepped in, rising to 31.71%. A falling promoter stake is not automatically bad, but it is worth noticing when the founders begin to hold less of the thing they built.

What replication would demand

Suppose a rival wanted Cipla's respiratory position. The bill is not mainly money — though clean rooms and milling equipment and years of trials cost many thousands of crores. The bill is mainly time and proof.

You would need to master particle engineering: milling and blending drugs to a one-to-five-micron window and holding that specification batch after batch, which is a manufacturing art with a long learning curve. You would need to design or license devices that deliver reliably across the messy range of real human breaths. You would need, for each product, the device and clinical data that convince regulators in each country that your inhaler is genuinely equivalent — a dossier that takes years per product and cannot be rushed. And you would need the field force and doctor relationships to get pulmonologists to prescribe your brand, because in branded markets a respiratory product is sold doctor by doctor.

The global competitors are formidable — the large multinational respiratory specialists who invented many of these devices, and a handful of other generic houses that have climbed the same learning curve. It is a small field precisely because the barriers are physical. That smallness is the good news for anyone already inside it.

Charlie's ledger: a good business asked to grow up

Reason as Munger would, across disciplines.

The learning curve is the central idea. A company that has made respiratory particles for decades knows things — subtle process knowledge, failure modes, regulatory relationships — that a newcomer cannot buy and must slowly earn. That accumulated know-how is a real competitive advantage, the kind that compounds quietly. Cipla's respiratory core has it.

But now apply Munger's discipline of looking at the whole animal, not the prize organ. Most of Cipla is not the protected respiratory franchise; it is ordinary generics and branded medicines in India, South Africa, and the United States, much of it exposed to exactly the commodity treadmill the inhalers escape. So the blended economics are a mixture of a good business and an average one, and the blend shows in the returns: a return on capital employed of 15.5% and a return on equity of 11.6% are decent but not spectacular — the numbers of a solid generic house with a valuable specialty pocket, not those of a pure moated compounder.

Invert: what erodes Cipla? A wave of successful inhaler copies arriving faster than expected would turn its best business ordinary. A stumble in the United States — a plant inspection failure or brutal generic price competition — would dent the whole. And the slow drift of the founding family out of the ownership raises the oldest governance question: whose company is this becoming, and will its capital be allocated as carefully as an owner-founder once allocated it?

There is a live warning in the recent numbers. After years of climbing — profit reached ₹5,269 crore in the year to March 2025 — the most recent year saw net profit fall to ₹3,862 crore, a decline the data shows as trailing profit growth of –26%, with operating margin slipping from 26% to 21%. One weak year proves nothing on its own, but it is a reminder that even the respiratory moat sits inside a business with plenty of commodity exposure, and commodity exposure means earnings can lurch.

What could management do this decade to widen the moat? Three things. First, lean into respiratory and other hard-to-copy inhaled and injectable products, where the physics does the defending, and treat plain oral generics as the cash engine rather than the growth story. Second, guard the United States plant compliance record obsessively, because that market rewards the franchise and punishes the careless. Third, deploy the nearly debt-free balance sheet — just ₹614 crore of borrowings against ₹34,270 crore of reserves — to acquire or build device and biologic capability, buying scarce know-how rather than commodity revenue.

Warren's turn: the owner's arithmetic

Buy the whole of Cipla and you would pay about ₹1,18,854 crore, roughly 31 times last year's earnings — a full price for a business whose returns sit in the low teens. The market is paying for the respiratory franchise and the clean balance sheet; an owner should ask whether the blended business earns that premium.

What comes with the purchase is genuinely solid. A nearly debt-free company: ₹614 crore of borrowings is trivial against the reserves, so essentially the entire business is financed by its owners, not its lenders. Real cash generation: ₹3,940 crore from operations last year, close to reported profit, confirming the earnings are cash and not accounting. And a long, unbroken record of growing the top line — sales rose from ₹11,345 crore a decade ago to ₹28,163 crore — even if the company itself concedes the pace has been modest, calling its own five-year sales growth of about 8% "poor."

Per-share progress has been real: earnings per share climbed from ₹14.71 to a peak of ₹65.28 before the recent dip to ₹48.02, and the share count has barely moved — no quiet dilution of owners. Dividends have run around a quarter of profit (a payout of 27% last year), a sensible balance between rewarding owners and reinvesting.

The honest reservations are two. First, predictability: the recent profit drop and margin slip show that even this business has cyclical, competitive exposure — it is not a serene annuity. Second, the return profile: an 11.6% return on equity is respectable but tells you the average rupee inside Cipla earns ordinary money, with the respiratory franchise earning more and the commodity generics earning less.

Is Cipla a business that can compound for decades? Yes, at a measured pace — and the verdict here is a narrow moat. The respiratory core is a genuine, physical, non-expiring advantage of the best kind; but it sits inside a larger body of commodity pharma, and the whole is priced as if the moat covered everything. A good business bought at a demanding price is a different proposition from a good business bought cheaply, and an owner should keep the distinction clear.

The structural risks

Copy risk at the crown jewels. Better generic technology and faster regulatory pathways could, over time, let more rivals reproduce complex inhalers, thinning the very oligopoly that makes them profitable.
US market exposure. Plant-inspection failures or savage generic price wars in America can hit earnings hard and fast, as the industry has repeatedly shown.
Commodity generics drag. The large non-respiratory business runs on the treadmill, capping blended returns and margins.
Ownership drift. A steadily falling promoter stake raises long-run questions about stewardship and capital discipline.
Pricing pressure at home. Government price caps on essential medicines, including respiratory drugs, can compress margins on the most-needed products.

The next twenty to thirty years

Reason from structural forces. Two of them point the same way for a respiratory company. First, air: urban air pollution across India and much of the developing world is a large, worsening driver of asthma and chronic lung disease, which expands the patient base for exactly Cipla's specialty. Second, ageing: older lungs need more care, and the world is ageing.

The science will keep raising the barrier in Cipla's favour. Inhaled delivery is being extended to new drugs and even to biologic molecules; "smart" inhalers that sense and time the dose are arriving; and each increment of device sophistication makes the copy harder, not easier — a rare case where technological progress deepens an incumbent's moat rather than eroding it. The open question is whether Cipla stays at the frontier of that device science or lets multinational specialists pull ahead while it defends yesterday's inhalers.

Cipla's founding conviction was that good medicine should reach the people who need it. The respiratory franchise is where that conviction and hard physics happen to coincide: a business that does real public good and, not by accident, is genuinely hard to copy. The child breathing again at three in the morning is the product. Whether the company keeps engineering the next, harder-to-copy way to reach her lungs is what the next decades will decide.

An Omaha Investments chapter. Educational material, not investment advice. Figures from Screener.in and NSE data via Angel One as of the date above.